Ligia A Pinto

Summary

Affiliation: National Cancer Institute
Country: USA

Publications

  1. ncbi Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    SAIC Frederick, Inc National Cancer Institute, Building 469, Room 120, Frederick, MD 21702, USA
    J Infect Dis 188:327-38. 2003
  2. ncbi T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation
    Sharon H Jackson
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 5:818-27. 2004
  3. ncbi Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    HPV Immunology Laboratory, SAIC-Frederick, Inc./NCI-Frederick, Frederick Building 469, Room 120, Frederick, MD 21702, USA
    Virology 353:451-62. 2006
  4. ncbi HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood
    Ligia A Pinto
    SAIC Frederick, Inc NCI Frederick, Room 120, Building 469, Frederick, MD 21702, USA
    Vaccine 23:3555-64. 2005
  5. ncbi Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry
    Ligia A Pinto
    NCI Frederick SAIC Frederick, Frederick, Maryland, USA
    Cytometry B Clin Cytom 63:47-55. 2005
  6. ncbi Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients
    Alfonso J Garcia-Pineres
    HPV Immunology Laboratory, Science Applications International Corporation Frederick National Cancer Institute Frederick, Frederick, MD 21702, USA
    J Immunol 182:1706-29. 2009
  7. ncbi DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies
    Alfonso J Garcia-Pineres
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick MD, USA
    J Immunol Methods 313:209-13. 2006
  8. ncbi Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles
    Alfonso Garcia Pineres
    HPV Immunology Laboratory, SAIC Frederick, Inc NCI Frederick, Frederick, Maryland 21702, USA
    Clin Vaccine Immunol 14:984-9. 2007
  9. ncbi HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Vaccine 29:2011-4. 2011
  10. ncbi Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States
    Vaccine 31:165-70. 2012

Collaborators

Detail Information

Publications25

  1. ncbi Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    SAIC Frederick, Inc National Cancer Institute, Building 469, Room 120, Frederick, MD 21702, USA
    J Infect Dis 188:327-38. 2003
    ..Future efficacy studies are needed to evaluate whether and/or how VLP vaccines confer protection against genital HPV infection and associated disease...
  2. ncbi T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation
    Sharon H Jackson
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 5:818-27. 2004
    ..Thus, mature T cells express a phagocyte-type NADPH oxidase that regulates elements of TCR signaling...
  3. ncbi Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
    Ligia A Pinto
    HPV Immunology Laboratory, SAIC-Frederick, Inc./NCI-Frederick, Frederick Building 469, Room 120, Frederick, MD 21702, USA
    Virology 353:451-62. 2006
    ..In summary, PBMC from HPV-16 VLP vaccine recipients can respond to L1VLP from heterologous HPV types, suggesting the presence of conserved T cell epitopes...
  4. ncbi HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood
    Ligia A Pinto
    SAIC Frederick, Inc NCI Frederick, Room 120, Building 469, Frederick, MD 21702, USA
    Vaccine 23:3555-64. 2005
    ....
  5. ncbi Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry
    Ligia A Pinto
    NCI Frederick SAIC Frederick, Frederick, Maryland, USA
    Cytometry B Clin Cytom 63:47-55. 2005
    ..The development of methods that would allow preservation of samples for flow cytometric analysis is important for the extension of this technology to field testing in settings where the equipment might be not readily accessible...
  6. ncbi Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients
    Alfonso J Garcia-Pineres
    HPV Immunology Laboratory, Science Applications International Corporation Frederick National Cancer Institute Frederick, Frederick, MD 21702, USA
    J Immunol 182:1706-29. 2009
    ..Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials...
  7. ncbi DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies
    Alfonso J Garcia-Pineres
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick MD, USA
    J Immunol Methods 313:209-13. 2006
    ..Therefore, this procedure seems suitable for standard immunologic assays...
  8. ncbi Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles
    Alfonso Garcia Pineres
    HPV Immunology Laboratory, SAIC Frederick, Inc NCI Frederick, Frederick, Maryland 21702, USA
    Clin Vaccine Immunol 14:984-9. 2007
    ..Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV...
  9. ncbi HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Vaccine 29:2011-4. 2011
    ..001; HPV45, p<0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine...
  10. ncbi Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States
    Vaccine 31:165-70. 2012
    ..Here, we evaluated the kinetics of neutralization titers and avidity of Cervarix(®)-induced antibodies up to 36 months of follow-up in unexposed and HPV infected women...
  11. ncbi Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals
    Joseph G Dauner
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Mol Cell Probes 26:73-80. 2012
    ..Therefore, a GuHCl-modified ELISA is an acceptable method that can be used to determine HPV-specific antibody avidity indices within a clinical trial setting...
  12. ncbi Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Clin Vaccine Immunol 15:60-4. 2008
    ..2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix...
  13. ncbi Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection
    Troy J Kemp
    HPV Immunology Laboratory, National Cancer Institute Frederick Science Applications International Corporation Frederick, Inc, Frederick, MD 21702, USA
    Cancer Epidemiol Biomarkers Prev 19:1954-9. 2010
    ..Defects in lymphoproliferative responses to mitogens/antigens in women >45 years old with a persistent type-specific human papillomavirus (HPV) infection have been reported...
  14. ncbi Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick Frederick, MD, USA
    Front Oncol 2:61. 2012
    ..Future studies should examine whether antigen-specific antibody responses induced by vaccination correlate across mucosal sites...
  15. ncbi Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection
    Rosalyn Baker
    HPV Immunology Laboratory, SAIC Frederick Inc, NCI Frederick, Frederick, MD 21702, USA
    Cytokine 53:282-5. 2011
    ..Further studies within a larger cohort are needed to define the generalities of these findings and any role adipokines have in persistent HPV infection...
  16. ncbi Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine
    Joseph G Dauner
    HPV Immunology Laboratory, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Vaccine 28:5407-13. 2010
    ..This is the first comprehensive study to correlate a variety of humoral aspects potentially associated with protective immunity following vaccination with a HPV16 L1 VLP vaccine...
  17. ncbi Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
    Troy J Kemp
    HPV Immunology Laboratory, SAIC Frederick Inc, NCI Frederick, Building 469, Room 120, Frederick, MD 21702, USA
    Vaccine 26:3608-16. 2008
    ....
  18. ncbi Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women
    Alfonso J Garcia-Pineres
    HPV Immunology Laboratory, Science Applications International Corporation Frederick, Inc National Cancer Institute Frederick, Frederick, Maryland, USA
    Cancer Res 66:11070-6. 2006
    ..Our results indicate that an impairment in host immunologic responses is associated to persistent HPV infection. The fact that effects were evident for all studied stimuli is suggestive of a generalized effect...
  19. ncbi Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine
    Alfonso J Garcia-Pineres
    SAIC Frederick NCI Frederick, Frederick, MD, USA
    Eur J Immunol 36:437-45. 2006
    ..These results suggest that DC-SIGN has a functional role in DC activation induced by HPV-16 L1-VLP, and thus highlight new aspects of DC interactions with HPV VLP...
  20. ncbi Comparison of benchtop microplate beta counters with the traditional gamma counting method for measurement of chromium-51 release in cytotoxic assays
    Dora Wallace
    National Cancer Institute-Frederick, National Institutes of Health/SAIC-Frederick, Frederick, Maryland 21702, USA
    Clin Diagn Lab Immunol 11:255-60. 2004
    ..Furthermore, this system reduces the amount of dry and mixed radioactive waste generated while using the same instrument for gamma- and beta-emitting isotopes...
  21. ncbi HIV inhibitory activity generated by antigen-stimulated cord blood leukocytes
    Ligia A Pinto
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    AIDS 17:1389-92. 2003
  22. ncbi Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27
    J Mohamad Fakruddin
    Laboratory of Human Retrovirology, Clinical Services Program CSP, Science Applications International Corporation SAIC Frederick, National Cancer Institute NCI, MD, USA
    Blood 109:1841-9. 2007
    ..Taken together, our studies identify a novel role of IL-27 in restricting HIV-1 replication and suggest that further examination of the inhibitory property of IL-27 may pave the way for a novel therapy for HIV-1 infection...
  23. ncbi Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 12:1449-56. 2003
    ....
  24. ncbi Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition
    Maria T Rugeles
    Universidad de Antioquia, Medellin, Colombia, The Experimental Immunology Branch, NCI, NIH, Bethesda, USA
    AIDS 17:481-6. 2003
    ..CONCLUSION: These findings indicate that the majority of the soluble HIV-1 inhibitory activity contained in the supernatants of mixed lymphocyte reactions is due to EDN or a closely related RNase...
  25. ncbi Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
    Francis J Dessy
    Research and Development, GlaxoSmithKline Biologicals, Rixensart, Belgium
    Hum Vaccin 4:425-34. 2008
    ..4 years) and the age of the vaccine recipient...